Pharmacy evidence record · researched 2026-08-20

Wells Pharmacy Network

Wells Pharmacy Network LLC

5 citations1 action records6 explicit unknowns

Compounded with

Semaglutide

First-party site lists commercial Wegovy semaglutide by Novo Nordisk.

Tirzepatide

First-party site lists commercial Zepbound tirzepatide by Eli Lilly.

Product evidence does not establish current availability.

Locations in the source record

  • 1210 SW 33rd Avenue, Ocala, FL 34474
  • 450 US Highway 51 BYP N, Dyersburg, TN 38024

Services named by sources

  • 503A patient-specific compounding
  • 503B outsourcing-facility services
  • Weight management
  • Wellness and anti-aging
  • Sexual wellness
  • Aesthetic dermatology
  • Thyroid/adrenal health

Regulatory compliance

503 pathway evidence

A pathway label describes which federal rules apply — it is not a quality claim.

Section 503A

Source-backed pathway evidence

verified first party

Section 503B

Source-backed pathway evidence

FDA's compounding-action index labels the Dyersburg location a 503B facility and the first-party site calls it FDA-registered. An exact row from the current weekly registry was not recovered, so the most-recent registration date is unverified.

Telehealth providers

No provider relationship is verified in the bound sources.

Clinic Scout links a provider only when an explicit source names the relationship.

Browse provider records

Regulatory history

Actions stay dated and bounded.

FDA compounding-action, Form 483, warning/untitled-letter, and current-503B sources were checked. The 2025 untitled letter and multiple Dyersburg inspection records were found; state-board action searches were not completed.

U.S. Food and Drug Administration · 2025-10-14

Untitled Letter

Following an April 14-25, 2025 inspection, FDA stated that products failed to meet section 503B conditions and described production-practice deficiencies.

Status not stated

What remains unverified

No Clinic Scout patient reviews are published for this pharmacy. Submissions go through manual moderation before anything appears here.

What this record verifies for you

5 evidence dimensions carry dated, source-backed verification.

Each line traces to a citation in the source list below — read the exact captured wording before relying on it.

No superiority claim is made for review volume, ratings, or patient sentiment.

Sources and exact captured wording

  1. first_party · accessed 2026-08-20
    Wells Pharmacy Network operates a 503A compounding pharmacy in Ocala, Florida as well as an FDA Registered 503B Outsourcing Facility in Dyersburg, Tennessee.
  2. fda · accessed 2026-08-20
    Wells Pharmacy Network LLC, Dyersburg, TN- 503B Facility
  3. fda · accessed 2026-08-20
    From April 14, 2025, to April 25, 2025, FDA investigators inspected your facility, Wells Pharmacy Network, LLC, located at 450 US Highway 51 BYP N, Dyersburg, TN 38024.
  4. first_party · accessed 2026-08-20
    Semaglutide (Wegovy®) Injectable (Commercial Product by Novo Nordisk)
  5. first_party · accessed 2026-08-20
    Tirzepatide (Zepbound®) Injection (Commercial Product by Eli Lilly Company)

Questions readers ask

Is Wells Pharmacy Network legit?

GLP Clinic Scout does not issue a blanket legitimacy verdict. This research record preserves 5 dated first-party or regulator citation(s), 1 regulatory/action record(s), and 6 explicitly unresolved field(s). Review the cited evidence and current license status before making a decision.

Still have questions? Read the research library or email us at [email protected].